Last reviewed · How we verify
Prilosec
Prilosec, marketed by Emory University, is a well-established drug in the proton pump inhibitor class. The key composition patent for Prilosec is set to expire in 2028, which currently provides a strong barrier to generic competition. The primary risk to Prilosec's market position is the potential increase in competition following the 2028 patent expiry.
At a glance
| Generic name | Prilosec |
|---|---|
| Sponsor | Emory University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants (PHASE1)
- Prevalence of Asymptomatic H Pylori Infection Among Patients Undergoing PCI and Impact of Its Eradication on Occurrence of GIT Symptoms and Bleeding" (PHASE3)
- Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing (PHASE4)
- Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer (PHASE2)
- OPEN Versus InTact Capsule Proton Pump Inhibitors for the Treatment of Marginal Ulcers (PHASE4)
- PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers (PHASE4)
- Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM) (PHASE1)
- A Trial of Omeprazole and Low Dose Aspirin to Identify Colorectal Biomarkers of Preventive Efficacy (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prilosec CI brief — competitive landscape report
- Prilosec updates RSS · CI watch RSS
- Emory University portfolio CI